Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Biosimilar vs Avastin in Advanced Non-Squamous NSCLC
NCT05654454Phase 3Recruiting
- Sponsor
- Mabscale
- Start
- May 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mabscale. Primary endpoint: Objective Response Rate at 18 weeks. Started May 2023; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05654454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654454.